MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine MOUNTAIN VIEW, Calif., Jan 16, 2008 -- MAP Pharmaceuticals, ...
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of ...
Like neutron stars and the certain executive branch politicians, Materials and Methods (M&M) sections just keep getting denser. Not content with shrinking the fonts to subatomic scale, many journals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results